FORT MYERS, Fla., Dec. 14, 2022 – American Oncology Network, LLC (AON) is pleased to announce that seven research studies co-authored by AON physicians were presented at the American Society of Hematology (ASH) Annual Meeting & Exposition, held December 10-13 in New Orleans, Louisiana.

More than 5,000 scientific abstracts are submitted each year, and those accepted for oral and poster presentations have gone through an extensive peer review process. The final abstracts featured at the ASH annual meeting represent important, novel research in the field.

The following AON physician investigators presented their research results during poster discussions and presentations at the ASH Annual Meeting & Exposition:

• Dr. Ruemu E. Birhiray of Hematology Oncology of Indiana presented and served as co-author of a study titled In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years (Abstract # 3255).
• Dr. Ralph V. Boccia of The Center for Cancer and Blood Disorders served as co-author of several studies titled Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E) (Abstract # 1598), Retrospective Assessment of Total Cost of Care in Non-Dialysis Dependent Chronic Kidney Disease Patients Receiving Parenteral Iron Therapy for Iron Deficiency Anemia (Abstract # 2185) and Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1–3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6) (Abstract # 4271).
• Dr. Arvind Chaudhry of Summit Cancer Centers served as co-author of several studies titled Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies (Abstract # 1587) and Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor–Intolerant Patients with Relapsed/Refractory B-Cell Malignancies (Abstract # 4176).
• Dr. Victor M. Priego of The Center for Cancer and Blood Disorders served as co-author of a study titled A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies (Abstract # 2893).

In addition, Dr. George Negrea of Low Country Cancer Care served as co-author of a study titled Digital Ischemia Associated with Profound Anemia: A Concerning Consequence of Treatment without Transfusion to be published on the ASH abstracts site.

“Being selected to present your research is an esteemed honor,” said AON Research Committee Chairman Dr. Ralph Boccia, Board-certified medical oncologist and hematologist at The Center for Cancer and Blood Disorders. “With high numbers of submitted materials being considered, the abstracts selected offer premier research findings that are deemed noteworthy and important to cancer care. Congratulations to these AON physicians for sharing their studies with the medical community, and we thank them for their dedication to improving patient care.”

“The field of cancer research is constantly evolving with new and revolutionary findings that transform patient care and treatment,” said AON CEO Todd Schonherz. “It is critical for physicians, and other members of the care team, to remain dedicated to continuing their education so that patients are receiving the right care at the right time. To have five AON physicians contributing their knowledge and expertise illustrates their commitment to advancing the industry forward by leading innovative research projects that elevate cancer care across the entire healthcare landscape.”

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 107 physicians and 89 nurse practitioners and physician assistants practicing across 18 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at AONcology.com.

Contact for more information:
Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

Four AON physicians joined the American Cancer Society as ambassadors
to raise money for the fight against breast cancer.

FORT MYERS, Fla., Nov. 21, 2022 – The American Oncology Network, LLC (AON) wrapped up Breast Cancer Awareness month recognizing its physicians who participated in the nationwide Real Men Wear Pink campaign: Dr. Christopher McCanless from Hematology Oncology Clinic in Baton Rouge, Louisiana, and Drs. Stephen “Fred” Divers, Sunil Kakadia and Robert Muldoon from Genesis Cancer and Blood Institute in Hot Springs, Arkansas.

“Our continuous goal is to increase awareness for all types of cancer, promote prevention and early detection, and highlight the benefits of local homegrown oncology practices,” said AON Chief Executive Officer Todd Schonherz. “Our physicians who acted as ambassadors during this month-long campaign not only raised money for this important cause but showed their support for the millions of patients who have been diagnosed with breast cancer. We are grateful for their commitment to the campaign.”

The Real Men Wear Pink campaign, an initiative of the American Cancer Society, is a nationwide movement to raise money and increase awareness of breast cancer. Ambassadors commit to wearing pink throughout the month of October, raising awareness for the cause through their personal and professional networks and encouraging monetary donations to help with the fight against breast cancer.

“Breast cancer is one of the most common cancers that affect women,” said AON Chief Medical Officer and medical oncologist at Genesis Cancer and Blood Institute Dr. Stephen “Fred” Divers. “Educating the community about the disease and how critical early detection is to survivorship is a top priority for me and oncologists across the nation. Participating in this campaign is just one way I feel I can continue teaching those around me so that accurate information is available.”

“I am honored to have participated in this year’s campaign,” said Dr. McCanless. “Cancer research and treatments are constantly evolving thanks to breakthrough studies and learnings. An added bonus, my patients appreciated my pink attire throughout the month, which brought a smile to many.”

Throughout the month, the physicians collectively raised over $6,500 for breast cancer research and patient support.

“This effort was more than just being a part of an initiative and raising money,” said Dr. Muldoon. “To me, it was about showing support for my breast cancer patients and survivors.”

“While cancer survivorship is increasing as a result of the advancements in care and treatments, breast cancer remains prevalent not just among women but men as well,” said Dr. Kakadia. “We all are able to work toward reducing the number of diagnoses per year — whether that is participating in a campaign such as this and raising money to ensuring you, your family and friends are receiving the recommended cancer screenings when it is needed.”

To learn more about AON, visit https://www.aoncology.com/. To learn more about Hematology Oncology Clinic and Genesis Cancer and Blood Institute, visit https://www.hocbr.com/ and https://www.genesiscancerblood.com/.

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 107 physicians and 89 nurse practitioners and physician assistants practicing across 18 states . The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at AONcology.com.

About Hematology Oncology Clinic
Specialists in the diagnosis and treatment of blood disorders and cancer, the Hematology/Oncology Clinic serves patients from offices in Baton Rouge, Zachary and Alexandria, Louisiana. Our Board-certified physicians include Dr. Gerald Miletello, Dr. Christopher McCanless, Dr. Michael Castine and Dr. Pavani Ellipeddi. The practice’s highly trained and experienced clinical staff consists of nurse practitioners, oncology-certified registered nurses and licensed practical nurses. Learn more at https://www.hocbr.com/.

About Genesis Cancer and Blood Institute
For 30 years, Genesis Cancer and Blood Institute has provided care to thousands of patients in Hot Springs and the surrounding communities. The center continues to focus on all aspects of treatment, encouraging positive attitudes and improving medicinal and nutritional therapies, all in a facility with an inviting and comforting atmosphere. Learn more at https://www.genesiscancerblood.com/.

Contact for more information:
Caroline Hewitt, Vice President of Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com

• American Oncology Network (AON) is a rapidly growing network of community-based oncology practices
• The proposed transaction values the combined company at a pro forma enterprise value of approximately $500 million

FORT MYERS, Fla. & LOS ANGELES, October 6, 2022 – American Oncology Network (“AON” or the “Company”), a rapidly growing network of community-based oncology practices, and Digital Transformation Opportunities Corp. (Nasdaq: DTOC) (“DTOC”), a special purpose acquisition company focused on the healthcare industry, today announced that they have entered into a definitive business combination agreement pursuant to which AON will become a public company (the “Business Combination”). Upon completion of the Business Combination, the combined company expects to be listed on Nasdaq.

Headquartered in Fort Myers, Florida, AON has grown significantly since it commenced operations in late 2018. The Company’s robust platform provides oncology practices with comprehensive support, access to revenue-diversifying adjacent services, and practice management expertise to empower physicians to make cancer care better. AON offers an innovative model of physician-led, community-based oncology management. With access to care-enhancing patient services (such as a centralized specialty pharmacy, diagnostics, pathology, as well as a fully integrated technology platform anchored by an oncology-specific electronic medical record system), a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences will be at the very pinnacle of cancer care today.

AON commenced operations in September 2018 and was founded by a senior leadership team who previously worked together and who have deep sector expertise within oncology. Since 2019, AON has generated compounded annual revenue growth of more than 60% through June 2022 and now generates more than $1 billion in annual revenue and operates profitably. AON’s platform currently includes 107 physicians and 24 practices across 71 locations in 18 states.

AON is well-positioned to continue growing driven by: (i) a fragmented and growing oncology industry with oncology medicine spend forecasted to grow at a 12% long-term CAGR, according to BCC Research; (ii) the ability to support the growth of AON’s physician partners through scaling ancillary services, such as clinical trials and dispensing of over 99% of oral oncolytics through AON’s specialty pharmacy, and introducing new service offerings; (iii) expanding AON’s existing service offering to address the broader oncology market; and (iv) growing the number of physician partners within AON’s network through both organic growth at existing practices as well as adding new practices.

Upon the closing of the Business Combination, AON’s senior leadership team will continue to serve in their current roles. The combined company will be led by AON’s Chief Executive Officer Todd Schonherz, President and Chief Development Officer Brad Prechtl, Chief Financial Officer David Gould, and Chief Medical Officer Dr. Fred Divers. AON’s existing board, which is composed of practicing medical oncologists, is expected to remain in place and will be joined by additional members affiliated with DTOC.

Management and Board of Directors’ Comments

Todd Schonherz, AON CEO, stated: “This transaction represents the next step in AON’s journey to become the leading platform for community-based oncology practices. Since launching the AON platform in 2018, we’ve been able to drive consistently strong growth by providing our physician partners with a strong suite of practice management tools and ancillary services as well as access to the financial benefits associated with being integrated with a scaled platform. We are excited to use the growth capital and partnership with the DTOC team to continue investing in technology and services that will support our physician partners and enhance the value proposition of AON.”

Kevin Nazemi, DTOC CEO, stated: “We are excited to partner with AON and believe that the Company is well-positioned to continue to build on its strong growth track record. We look forward to supporting AON as it continues to bring its services to more physician partnerships. We launched DTOC with the commitment to our investors to partner with a high growth platform that was leveraging technology to drive improvement within the healthcare industry and we couldn’t be more excited to fulfill that commitment today through our partnership with AON.”

Dr. Stephen “Fred” Divers, AON Chief Medical Officer, added: “AON was founded with the mission of providing community-based oncology practices with a platform that can support robust practice growth and deliver patient-centric care. We believe that the DTOC partnership will further enhance AON’s platform, allowing our physician partners to continue growing and thriving as part of our network. We look forward to continuing to grow our network of physician partners and supporting them with our physician practice management platform.”

Details of the Business Combination

Under the terms of the definitive business combination agreement, the proposed Business Combination values the combined company at a pro forma enterprise value of approximately $500 million. Existing AON equity holders will roll 100% of their equity in AON. DTOC’s sponsor has agreed to subject its shares in the combined company to lock-up restrictions and various earnout thresholds.

The proposed Business Combination, which has been approved by DTOC’s board of directors and AON’s board of managers and members, is expected to close in the first half of 2023. The closing of the proposed Business Combination is subject to approval by DTOC’s stockholders and other customary closing conditions, including any applicable regulatory approvals.

The description of the proposed Business Combination contained herein is only a summary and is qualified in its entirety by reference to the definitive agreement relating to the Business Combination, a copy of which will be filed by DTOC with the Securities and Exchange Commission (“SEC”) as an exhibit to a Current Report on Form 8-K, which can be accessed through the SEC’s website at www.sec.gov.

Advisors

Paul Hastings LLP is serving as legal advisor to DTOC. Woolery & Co. PLLC and Dentons US LLP are serving as legal advisors to AON.

About AON

The American Oncology Network, LLC (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 107 physicians practicing across 18 states. The executive management team of AON encompasses members with an average of more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients. Learn more at www.aoncology.com.

About DTOC

Digital Transformation Opportunities Corp. is a blank check company, led by Kevin Nazemi, former Co-Founder and Co-CEO of Oscar Health, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. DTOC’s Board of Directors includes Kevin Nazemi, Brad Fluegel (former Chief Strategy Officer of Walgreens and Anthem), Jim Moffatt (Former Vice Chairman and Global CEO of Deloitte Consulting), and Heather Zynczak (Former Chief Marketing Officer of Pluralsight and Domo). DTOC is focused on businesses operating in the healthcare industry. To learn more about Digital Transformation Opportunities Corp., visit www.dtocorp.com.

Important Information about the Transaction and Where to Find It

In connection with the proposed Business Combination, DTOC intends to file with the SEC a proxy statement, which will be mailed (if and when available) to all DTOC stockholders once definitive (the “Proxy Statement”), which will be distributed to holders of shares of DTOC common stock in connection with DTOC’s solicitation of proxies for the vote by DTOC stockholders with respect to the Business Combination as well as other matters as may be described in the Proxy Statement. DTOC STOCKHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ, WHEN AVAILABLE, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION, AS THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT DTOC, AON AND THE PROPOSED BUSINESS COMBINATION. This press release does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. When available, the Proxy Statement and other relevant materials for the proposed Business Combination will be mailed to stockholders of DTOC as of a record date to be established for voting on the proposed Business Combination. DTOC stockholders will also be able to obtain copies of the definitive proxy statement and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov.

Participants in the Solicitation

DTOC and its directors and executive officers may be deemed participants in the solicitation of proxies from DTOC’s stockholders with respect to the proposed Business Combination. A list of the names of those directors and executive officers and a description of their interests in DTOC is contained in DTOC’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on April 13, 2022 and is available free of charge at the SEC’s website at www.sec.gov. Additional information regarding the interests of such participants will be contained in the Proxy Statement for the proposed Business Combination.

AON and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of DTOC in connection with the proposed Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed Business Combination will be included in the Proxy Statement for the proposed Business Combination.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements. Forward-looking statements generally relate to future events including future financial or operating performance of DTOC or AON. For example, projections of future revenue and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by DTOC and its management, and AON and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond DTOC’s and AON’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) DTOC’s ability to complete the Business Combination and to raise additional capital; (2) the outcome of any legal proceedings that may be instituted against DTOC, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the stockholders of DTOC, to obtain financing to complete the Business Combination, or to satisfy other conditions to closing; (4) the amount of redemption requests made by DTOC’s public stockholders; (5) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (6) the ability to meet stock exchange listing standards following the consummation of the Business Combination; (7) the risk that the Business Combination disrupts current plans and operations of AON as a result of the announcement and consummation of the Business Combination; (8) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain key relationships and retain its management and key employees; (9) costs related to the Business Combination; (10) changes in applicable laws or regulations; (11) the possibility that AON or the combined company may be adversely affected by other economic, business, and/or competitive factors; (12) AON’s estimates of expenses and profitability; (13) the failure to realize anticipated pro forma results or projections and underlying assumptions; and (14) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in DTOC’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on April 13, 2022 and DTOC’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 filed with the SEC on May 17, 2022, in the Proxy Statement relating to the Business Combination to be filed with the SEC, and in subsequent filings with the SEC. DTOC and AON caution that the foregoing list of factors is not exclusive or exhaustive and investors should not place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. If any of these risks materialize or DTOC’s or AON’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither DTOC nor AON presently know or that DTOC and AON currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect DTOC’s and AON’s expectations, plans or forecasts of future events and views as of the date of this communication. DTOC and AON anticipate that subsequent events and developments will cause DTOC’s and AON’s assessments to change. However, while DTOC may elect to update these forward-looking statements at some point in the future, DTOC and AON specifically disclaim any obligation to do so, unless required by applicable law. These forward-looking statements should not be relied upon as representing DTOC’s or AON’s assessments as of any date subsequent to the date of this communication. Neither DTOC nor AON gives any assurance that AON or DTOC will achieve its expectations. Accordingly, undue reliance should not be placed upon the forward-looking statements.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.

References to Websites in this Press Release

The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Contacts

For AON:
David Gould, Chief Financial Officer
David.Gould@aoncology.com

For DTOC:
Kyle Francis, Chief Financial Officer
kyle@dtocorp.com

New oncology-hematology clinic opens in mid-September, delivering additional cancer care and treatments
to the Johns Creek community.

FORT MYERS, Fla. and JOHNS CREEK, Ga., September 20, 2022 – American Oncology Network, LLC (AON) is pleased to announce the opening of Cancer and Blood Specialists of Georgia (CBSG), a new community-based oncology practice located in Johns Creek. The CBSG clinic is located at 6985 McGinnis Ferry Road, Suite 100, is set to open on September 22 and is accepting new patients.

The CBSG team includes Board-certified medical oncologist Sreekanth Reddy, MD, who will provide a comprehensive range of treatments for patients diagnosed with cancer and blood disorders. Dr. Reddy has over 18 years of experience treating oncology and hematology patients in the metro-Atlanta area.

CBSG is a partnering practice with AON, a nationwide network of community-based oncology practices. AON supports hometown practices, their physicians and patients to ensure the latest in cancer care and treatments are readily available and accessible at the local level. Through the partnership, CBSG is able to provide multiple services to patients such as infusion therapy, centralized laboratory and pathology, oral cancer medications and financial counseling.

“Our partnership with AON is a valuable one that allows our healthcare team to be patient-first and focused on delivering high-quality care and services to every patient,” said Dr. Reddy, lead medical oncologist at CBSG. “Through the partnership, our patients benefit greatly and will have access to a plethora of care and services, including care management, that will have a great influence on their overall health journey.”

“Community-based practices are the heart and soul of delivering patient-first care that is accessible and affordable, which is very important in cancer care,” said Brad Prechtl, MBA, AON’s president and chief development officer. “Dr. Reddy is dedicated to ensuring patient-first care remains intact in his practice. I am honored to say that we are gaining a well-practiced physician who is dedicated to driving patient-first cancer care in his community.”

“We are excited to extend a warm AON welcome to Dr. Reddy and the team at Cancer and Blood Specialists of Georgia,” said Todd Schonherz, AON’s chief executive officer. “Dr. Reddy is an excellent physician and brings ample experience to the oncology network in and around Atlanta. We look forward to supporting him, his practice as well as his patients.”

For more information about Cancer and Blood Specialists of Georgia, visit https://www.cancerbloodspecialistsga.com/.

###

About American Oncology Network, LLC
The American Oncology Network, LLC (AON), an Inc. 5000-recognized company, is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 89 nurse practitioners and physician assistants practicing across 16 states. The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at aoncology.com.

About Cancer and Blood Specialists of Georgia
Specialists in the diagnosis and treatment of cancer and blood disorders, Cancer and Blood Specialists of Georgia providers have been serving patients in the Johns Creek, Georgia and surrounding Atlanta areas for more than 18 years. As a community-based practice, we offer a full range of exceptional cancer services, providing the highest quality treatment based on research and focused on the whole person.

Contact for more information:
Caroline Hewitt, Vice President of  Marketing
American Oncology Network, LLC
Caroline.Hewitt@AONcology.com